Driver Versus Passenger Mutations in Tumors

Piraino, Scott W.; Thomas, Valentina; O′Donovan, Peter; Furney, Simon J.

doi:10.1016/b978-0-12-801238-3.65045-6

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, heterogeneous populations of tumor cells can have the same or different genome content depending on the type of heterogeneity ( Bedard et al, 2013 ). Hereupon, tumor heterogeneity can be divided into three types: 1) intertumor heterogeneity which is related to the variation of tumor cells among different patients, 2) intersite heterogeneity which is referred to the variation of cells among distinct tumors within a patient such as tumors in the primary site and tumors in the metastatic site, and 3) intratumor heterogeneity which is linked with heterogeneous populations of cells in a single tumor ( Piraino et al, 2019 ). Oncology studies were shown that the cancer stem cells (CSCs) model is one of the models responsible for the generation of heterogeneous populations of cells, especially intratumor heterogeneity type ( Prasetyanti and Medema, 2017 ; Turnquist et al ).…”

Section: Introductionmentioning

confidence: 99%

Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes

et al. 2022

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are subpopulation of cells which have been demonstrated in a variety of cancer models and involved in cancer initiation, progression, and development. Indeed, CSCs which seem to form a small percentage of tumor cells, display resembling characteristics to natural stem cells such as self-renewal, survival, differentiation, proliferation, and quiescence. Moreover, they have some characteristics that eventually can demonstrate the heterogeneity of cancer cells and tumor progression. On the other hand, another aspect of CSCs that has been recognized as a central concern facing cancer patients is resistance to mainstays of cancer treatment such as chemotherapy and radiation. Owing to these details and the stated stemness capabilities, these immature progenitors of cancerous cells can constantly persist after different therapies and cause tumor regrowth or metastasis. Further, in both normal development and malignancy, cellular metabolism and stemness are intricately linked and CSCs dominant metabolic phenotype changes across tumor entities, patients, and tumor subclones. Hence, CSCs can be determined as one of the factors that correlate to the failure of common therapeutic approaches in cancer treatment. In this context, researchers are searching out new alternative or complementary therapies such as targeted methods to fight against cancer. Molecular docking is one of the computational modeling methods that has a new promise in cancer cell targeting through drug designing and discovering programs. In a simple definition, molecular docking methods are used to determine the metabolic interaction between two molecules and find the best orientation of a ligand to its molecular target with minimal free energy in the formation of a stable complex. As a comprehensive approach, this computational drug design method can be thought more cost-effective and time-saving compare to other conventional methods in cancer treatment. In addition, increasing productivity and quality in pharmaceutical research can be another advantage of this molecular modeling method. Therefore, in recent years, it can be concluded that molecular docking can be considered as one of the novel strategies at the forefront of the cancer battle via targeting cancer stem cell metabolic processes.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes

et al. 2022

View full text Add to dashboard Cite

show abstract

MRI Radiogenomics in Precision Oncology: New Diagnosis and Treatment Method

Yin

Gao

Wang

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Precision medicine for cancer affords a new way for the most accurate and effective treatment to each individual cancer. Given the high time-evolving intertumor and intratumor heterogeneity features of personal medicine, there are still several obstacles hindering its diagnosis and treatment in clinical practice regardless of extensive exploration on it over the past years. This paper is to investigate radiogenomics methods in the literature for precision medicine for cancer focusing on the heterogeneity analysis of tumors. Based on integrative analysis of multimodal (parametric) imaging and molecular data in bulk tumors, a comprehensive analysis and discussion involving the characterization of tumor heterogeneity in imaging and molecular expression are conducted. These investigations are intended to (i) fully excavate the multidimensional spatial, temporal, and semantic related information regarding high-dimensional breast magnetic resonance imaging data, with integration of the highly specific structured data of genomics and combination of the diagnosis and cognitive process of doctors, and (ii) establish a radiogenomics data representation model based on multidimensional consistency analysis with multilevel spatial-temporal correlations.

show abstract

Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints

Mathew

Berry

Yang

et al. 2022

IJMS

View full text Add to dashboard Cite

Glioblastoma multiforme is the most lethal intrinsic brain tumor. Even with the existing treatment regimen of surgery, radiation, and chemotherapy, the median survival time is only 15–23 months. The invasive nature of this tumor makes its complete removal very difficult, leading to a high recurrence rate of over 90%. Drug delivery to glioblastoma is challenging because of the molecular and cellular heterogeneity of the tumor, its infiltrative nature, and the blood–brain barrier. Understanding the critical characteristics that restrict drug delivery to the tumor is necessary to develop platforms for the enhanced delivery of effective treatments. In this review, we address the impact of tumor invasion, the molecular and cellular heterogeneity of the tumor, and the blood–brain barrier on the delivery and distribution of drugs using potential therapeutic delivery options such as convection-enhanced delivery, controlled release systems, nanomaterial systems, peptide-based systems, and focused ultrasound.

show abstract

Driver Versus Passenger Mutations in Tumors

Cited by 3 publications

References 5 publications

Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes

Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes

MRI Radiogenomics in Precision Oncology: New Diagnosis and Treatment Method

Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints

Contact Info

Product

Resources

About